Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altabax Review Highlights Ethical Use Of Placebo In Pediatric Populations

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

GlaxoSmithKline’s pivotal trial for Altabax provided strong evidence that it could be ethical to use a placebo and withhold treatment for dermatological indications – even in a pediatric population – as long as safety measures were employed, FDA reviewers concurred.

You may also be interested in...



NovaBay's Non-Antibiotic Anti-Infective Shows Efficacy In Impetigo Trial

NovaBay is a step closer to commercializing the first non-antibiotic for treating an infection typically treated with antibiotics, now that its topical gel yielded a 90 percent cure rate in a Phase IIa proof-of-concept trial against impetigo

Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China

Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel